Join the Ulcerative Colitis - Active group to help and get support from people like you.
Ulcerative Colitis - Active News (Page 2)
Crohn's, Colitis Care Take Big Financial Toll on Patients
THURSDAY, Oct. 10, 2024 – Inflammatory bowel conditions such as Crohn’s disease and colitis cause intense financial pressure as well as physical distress, a new study shows. More than 40% of people w...
Anti-TL1A Monoclonal Antibody, Tulisokibart, Aids Ulcerative Colitis
FRIDAY, Oct. 4, 2024 – Tulisokibart, a tumor necrosis factor-like cytokine 1A monoclonal antibody, is more effective in inducing clinical remission in patients with moderately to severely active...
Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis
HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya® (guselkumab) for the treatment of adults with m...
Treatment Could Be New Option for People Battling Ulcerative Colitis
FRIDAY, Sept. 27, 2024 – An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The...
FDA Approves Tremfya for Ulcerative Colitis
MONDAY, Sept. 16, 2024 – The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis. Tremfya is the...
RSV Infection With Inflammatory Bowel Disease Ups Risk for Hospitalization
WEDNESDAY, Aug. 28, 2024 – Adult patients with inflammatory bowel disease (IBD) and respiratory syncytial virus (RSV) infection have an increased risk for hospitalization, according to a study...
Televisit Outpatient Care Feasible for Inflammatory Bowel Disease
FRIDAY, Aug. 23, 2024 – Televisit-delivered outpatient care for inflammatory bowel disease (IBD) is not associated with a higher risk for IBD-related hospitalization, according to a study published...
4 Tips to Keeping Your Gut Healthy and Free of IBD
TUESDAY, Aug. 6, 2024 – Almost 2.4 million Americans are thought to suffer from the pain and disability of inflammatory bowel disorder (IBD), a type of autoimmune illness that includes ulcerative...
Rinvoq (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
NORTH CHICAGO, Ill., March 16, 2022 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib) for the treatment of ...
Janssen Announces FDA Approval of Stelara (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
HORSHAM, PENNSYLVANIA, October 21, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration’s (FDA) approval of Stelara (ustekinumab) for ...
FDA Medwatch Alert: FDA Approves Boxed Warning About Increased Risk of Blood Clots and Death with Higher Dose of Tofacitinib (Xeljanz, Xeljanz XR)
July 26, 2019 – The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz...
FDA Approves Ixifi (infliximab-qbtx), a Biosimilar to Remicade
December 13, 2017 – Pfizer Inc. (NYSE:PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Ixifi (PF-06438179, infliximab-qbtx), a chimeric...
FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira
Ridgefield, Conn., August 29, 2017 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Cyltezo, a biosimilar to Humira, in a p...
FDA Approves Renflexis (infliximab-abda), a Biosimilar to Remicade
INCHEON, Korea – April 24, 2017 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar referencing Rem...
FDA Approves Uceris (budesonide) Rectal Foam for Ulcerative Colitis
RALEIGH, N.C., October 8, 2014 – Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Food and Drug Administration (FDA) has granted final approval for Uceris (budesonide) rectal foam...
Further information
Related condition support groups
Related drug support groups
prednisone, methylprednisolone, betamethasone, cortisone, Medrol, Stelara, prednisolone, budesonide, ustekinumab